News

May 11, 2021May 11, 2021

Arimoclomol Fails to Show Efficacy in Phase 3 Trial, Topline Data Show

News

A Phase 3 clinical trial evaluating Orphazyme’s investigational oral therapy arimoclomol for amyotrophic lateral sclerosis (ALS) has failed to meet its primary and key secondary goals. While no safety issues were ... Read more

May 10, 2021May 10, 2021

Netherlands Researcher Wins 2021 Sheila Essey Award for Genetics Work

News

Jan Veldink, a neurologist from the Netherlands whose work in the genetics of amyotrophic lateral sclerosis (ALS) has led to important discoveries about disease risk, won the 2021 Sheila Essey ... Read more

May 7, 2021May 7, 2021

Phase 2 Study of RT001 in ALS Patients Fully Enrolled, Retrotope Says

News

A Phase 2 clinical trial evaluating oral RT001 — Retrotope’s experimental synthetic fatty acid — as a treatment of amyotrophic lateral sclerosis (ALS) is fully enrolled, the company announced. The enrollment target of ... Read more

May 6, 2021May 6, 2021

Boosting Cell Stress Response May Be Promising Therapy Approach

News

A combination of guanabenz — an approved therapy for high blood pressure — plus riluzole slowed disease progression in adults with early amyotrophic lateral sclerosis (ALS), particularly those with bulbar onset disease, ... Read more

May 5, 2021May 5, 2021

EMA Group Favors Naming SLS-005 an Orphan Drug for ALS

News

A committee with the European Medicines Agency favors designating Seelos Therapeutics‘ investigational therapy SLS-005 (trehalose) an orphan drug as a potential treatment of amyotrophic lateral sclerosis (ALS), the company announced in a press ... Read more

May 4, 2021May 4, 2021

Variety of Advocacy, Fundraising Events Mark ALS Awareness Month

News

National Amyotrophic Lateral Sclerosis Awareness Month, recognized in the U.S. each May since 1992, continues to unite patients, family, friends, and advocacy groups around shared goals of raising public awareness ... Read more

May 3, 2021May 3, 2021

MDA Golf Events to Support Neuromuscular Research, Patient Care

News

Registration is now open for fundraising events at four championship golf courses, whose fees will be used to fund research, care, and advocacy for neuromuscular disorders such as amyotrophic lateral ... Read more

April 30, 2021April 30, 2021

Biogen Agrees to Tofersen Access in July for Rapidly Advancing ALS

News

People with very rapidly progressing familial amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene may gain early access to Biogen’s experimental therapy tofersen by mid-July, the company announced. This marks ... Read more

April 29, 2021April 29, 2021

$60K Grant to Support Work on Biomarkers for ALS, Like Disorders

News

Applications for a $60,000 one-year grant are now open for researchers working to discover or validate biomarkers for amyotrophic lateral sclerosis (ALS) or a similar disorder. Those interested in trying ... Read more

April 28, 2021April 28, 2021

#AANAM – Progression May Be Evident in About 1.5 Years of Radicava Start

AAN 2021, News

Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Amyotrophic lateral sclerosis (ALS) patients ... Read more